Cost-effectiveness analysis in Parkinson's disease: Determining the value of interventions

Movement Disorders

Volumn 15, Issue 3, 2000, Pages 439-445

  Siderowf, Andrew D ^a,c   Holloway, Robert G ^b   Stern, Matthew B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; PRAMIPEXOLE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; GENERAL PRACTITIONER; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH MAINTENANCE ORGANIZATION; HUMAN; MEDICAL SPECIALIST; MEDICARE; PARKINSON DISEASE; PATIENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOCIETY; TIME; UTILIZATION REVIEW;

CLINICAL TRIALS; COST-BENEFIT ANALYSIS; HUMANS; PARKINSON DISEASE; QUALITY-ADJUSTED LIFE YEARS; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 0034106354     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8257(200005)15:3<439::AID-MDS1004>3.0.CO;2-F     Document Type: Article

References (47)

1. Levit K, Cowan C, Braden B, et al. National health expenditures in 1997: more slow growth. Health Affairs 1998;17:99-110.
2. Gold M. The changing US health care system: challenges for responsible public policy. Milbank Q 1999;77:3-37.
3. Grumbach K, Bodenheimer T. Health care policy: a clinical approach. Mechanisms for controlling costs. JAMA 1995;273:1223-1230.
4. Weinstein MC. High-priced technology can be good value for money. Ann Intern Med 1999;130:857-858.
5. Lundberg GD. A JAMA theme issue on quality of care: a new proposal and a call to action. JAMA 1997;278:1615-1616.
6. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253-1258.
7. O'Brien BJ, Drummond MF, Richardson WS, Levine M. Users' guide to the medical literature. XIII: how to use and article on economic analysis of clinical practice. B: what are the results and will they help me in caring for my patients? JAMA 1997;277:1802-1806.
8. Drummond MF, Richardson WS, O'Brien BJ, et al. Users' guide to the medical literature. XIII: how to use an article on economic analysis of clinical practices. JAMA 1997;277:1552-1557.
9. Russell LB, Gold MR, Siegel JE. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996;276:1172-1177.
10. Eisenberg JM. Clinical economics: a guide to the economic analysis of clinical practices. JAMA 1989;262:2879-2886.
11. Carter J, Nutt JG. Family caregiving: a neglected and hidden part of health care delivery. Neurology 1999;51:1245-1246.
12. Drummond MF, O'Brien B, Stoddard GL, Torrance GW. Cost-utility analysis. In: Methods for the Economic Evaluation of Health Care Programmes. New York, NY: Oxford University Press, 1997:138-204.
13. Detsky AS, Naglie IG. A clinician's guide to cost-effectiveness analysis. Ann Intern Med 1990;113:147-154.
14. Drummond MF, Davies L. Economic analysis alongside clinical trials: revisiting the methodological issues, Int J Technol Assess Health Care 1991;7:561-573.
15. Polsky D, Glick HA, Willke R, Schulman K. Confidence intervals for cost-effectiveness rations: a comparison of four methods. Health Econ 1997;6:243-252.
16. Mushlin AI, Hall WJ, Zwanziger J, et al. The cost effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Circulation 1998;97:2129-2135.
17. Click H, Willke R, Polsky D, et al. Economic analysis of tirilazad mesylate for aneurysmal subarachnoid hemorrhage, Int J Neurosci 1998;14:145-160.
18. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992;146:473-481.
19. Singer E. Social costs of Parkinson's disease. Journal of Chronic Diseases 1973;26:243-254.
20. Dodel RC, Eggert KM, Singer MS, et al. Cost of drug treatment in Parkinson's disease. Mov Disord 1998;13:249-254.
21. Dodel RC, Singer MS. Kohne-Volland R, et al. The economic impact of Parkinson's disease. PharmacoEconomics 1998;14:299-312.
22. Whetten-Goldstein K, Sloan F, Kulas E, et al. The burden of Parkinson's disease on society, family, and the individual. J Am Geriatr Soc 1997;45:844-849.
23. Chrischilles EA, Rubenstein LM, Voelker MD, et al. The health burdens of Parkinson's disease. Mov Disord 1998;13:406-413.
24. Rubenstein LM, Chrischilles EA, Voelker MD. The impact of Parkinson's disease on health status, health expenditures and productivity. PharmacoEconomics 1997;12:486-497.
25. The Average Per-Patient Costs of Parkinson's Disease. New York, NY: John Robbins Associates. Inc. 1998:1-12.
26. Parkinson's Disease: Hope Through Research. Bethesda, MD: Office of Communication and Public Liaison, NINDS, 1994.
27. Tanner CM, Goldman SM. Epidemiology of Parkinson's disease. Neurol Clin 1996;14:317-333.
28. The Cost of Disorders of the Brain. Washington, DC: National Foundation for Brain Research, 1992:1-71.
29. Schappert S. Office visits to neurologists: United States, 1991-92. Advance Data (CDC) 1995;267:1-20.
30. Haupt B. An overview of home health and hospice care patients: 1996 national home and hospice care survey. Advance Data (CDC) 1998;297:1-36.
31. Goetz, CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993;43:2227-2229.
32. Mitchell SL, Kiely DK, Kiel DP, Lipsitz LA. The epidemiology, clinical characteristics, and natural history of older nursing home residents with a diagnosis of Parkinson's disease. J Am Geriatr Soc 1996;44:394-399.
33. Siderowf A, Xu G. Bakst A, et al. Factors influencing resource use in patients with Parkinson's disease [Abstract]. Ann Neurol 1999. 46:508A.
34. Siderowf A, Holloway R, Mushlin AI. Cost-effectiveness of pallidotomy and add-on medical therapy in advanced Parkinson's disease [Abstract]. Ann Neurol 1998;44:517.
35. Hempel AG, Wagner ML, Maaty MA. Sage JI. Pharmacoeconomic analysis of using Sinemet CR over standard Sinemet in parkinsonian patients with motor fluctuations. Ann Pharmacother 1998;32: 878-883.
36. McFarland HR. Treatment of Parkinson's disease [Letter]. Neurology 1993;43:1056.
37. Kurlan R, Clark S. Shoulson I, Penney JB. Economic impact of protective therapy for early Parkinson's disease [Abstract]. Ann Neurol 1998;24:153.
38. Gunderson CH. The impact of new pharmaceutical agents on the cost of neurologic care. Neurology 1995;45:569-572.
39. Hoerger TJ. Bala MV, Rowland C, et al. Cost-effectiveness of pramipexole in Parkinson's disease in the United States. PharmacoEconomics 1998;14:541-557.
40. Dorman P, Slattery J, Farrell B, et al. Qualitative comparison of the reliability of health status assessments with the EuroQol and SF-36 questionnaires after stroke. United Kingdom Collaborators in the International Stroke Trial. Stroke 1998;29:63-68.
41. Manone M, Kanter DS, Glynn RJ, et al. Variability in length of hospitalization for stroke: the role of managed care in an elderly population. Arch Neurol 1996;53:875-880.
42. Mitchell JB, Ballard PA, Whisnant JP, et al. What role do neurologists play in determining the costs and outcomes of stroke patients? Stroke 1996;27:1937-1943.
43. Graham JD, Thompson KM, Goldie SJ, et al. The cost-effectiveness of air bags by seating position. JAMA 1997;278: 1418-1425.
44. Gould MK, Dembitzer AD, Sanders GD. Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Ann Intern Med 1999;130:789-799.
45. McNamara RL. Lima JA, Whelton PK, Powe NR. Echocardiographic identification of cardiovascular sources of emboli to guide clinical management of stroke: a cost-effectiveness analysis. Ann Intern Med 1997;127:775-787.
46. CDC Diabetes Cost-Effectiveness Study Group. Centers for Disease Control and Prevention. The cost-effectiveness of screening for type 2 diabetes. JAMA 1998;280:1757-1763.
47. Lee TT, Solomon NA, Heidenreich PA, et al. Cost-effectiveness of screening for carotid stenosis in asymptomatic patients. Ann Intern Med 1997;126:337-346.